A Randomized Controlled Trial of Palifermin (Recombinant Human Keratinocyte Growth Factor) for the Treatment of Inadequate CD4+ T-Lymphocyte Recovery in Patients with HIV-1 Infection on Antiretroviral Therapy.

MLA

Jacobson, Jeffrey M., et al. “A Randomized Controlled Trial of Palifermin (Recombinant Human Keratinocyte Growth Factor) for the Treatment of Inadequate CD4+ T-Lymphocyte Recovery in Patients with HIV-1 Infection on Antiretroviral Therapy.” JAIDS: Journal of Acquired Immune Deficiency Syndromes, vol. 66, no. 4, Aug. 2014, pp. 399–406. EBSCOhost, https://doi.org/10.1097/QAI.0000000000000195.

APA

Jacobson, J. M., Wang, H., Bordi, R., Zheng, L., Gross, B. H., Landay, A. L., Spritzler, J., Routy, J.-P., Benson, C., Aberg, J., Tebas, P., Haas, D. W., Tiu, J., Coughlin, K., Purdue, L., & Sekaly, R.-P. (2014). A Randomized Controlled Trial of Palifermin (Recombinant Human Keratinocyte Growth Factor) for the Treatment of Inadequate CD4+ T-Lymphocyte Recovery in Patients with HIV-1 Infection on Antiretroviral Therapy. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 66(4), 399–406. https://doi.org/10.1097/QAI.0000000000000195

Chicago

Jacobson, Jeffrey M., Hongying Wang, Rebeka Bordi, Lu Zheng, Barry H. Gross, Alan L. Landay, John Spritzler, et al. 2014. “A Randomized Controlled Trial of Palifermin (Recombinant Human Keratinocyte Growth Factor) for the Treatment of Inadequate CD4+ T-Lymphocyte Recovery in Patients with HIV-1 Infection on Antiretroviral Therapy.” JAIDS: Journal of Acquired Immune Deficiency Syndromes 66 (4): 399–406. doi:10.1097/QAI.0000000000000195.